Global Hepatorenal Syndrome Market - 2023-2030

Global Hepatorenal Syndrome Market - 2023-2030

Global Hepatorenal Syndrome Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Hepatorenal syndrome (HRS) is a multiorgan condition affecting the kidneys and the liver. It is a cause of acute kidney injury that can be seen in those with acute or chronic liver disease. The hepatorenal syndrome occurs when the kidneys stop working well in people with serious liver problems.

It usually occurs in people who have had chronic, progressive liver disease for some time and who are on the threshold of liver failure. Less urine is produced by the body, so waste products that contain nitrogen build up in the bloodstream.

Market Dynamics: Drivers & Restraints

Increasing incidence of liver damage and liver cirrhosis

The increasing prevalence of liver damage and cirrhosis is expected to raise the market growth. Increasing cases will increase the demand for treatment of the condition. Severe liver damage will stop the functioning of the kidneys which will lead to hepatorenal syndrome.

For instance, according to the American Liver Foundation, it is estimated that more than 100 million people in the U.S. have some form of liver disease. 4.5 million U.S. adults have been diagnosed with liver disease. Thus, the above factors are expected to drive market growth in the forecast period.

Additionally, according to the report by the National Institute of Health in 2022, it is estimated that liver disease alone has contributed to 18.3% of deaths globally. Thus the increasing liver diseases are expected to drive the market growth in the forecast period.

Restraint

Side effects associated with the drugs

Side effects associated with the drugs that are used against the condition are expected to hinder market growth. For instance, the most common side effects of terlipressin administration were paleness, increased blood pressure, peripheral ischemia, abdominal pain, nausea, diarrhea, and headache. Thus, the above factors are expected to hamper market growth in the forecast period.

Segment Analysisn

The global hepatorenal syndrome market is segmented based on type, treatment, end-user, and region.

Terlipressin Infusion accounted for 56.4% of the market share

Hepatorenal syndrome is one of numerous possible causes of acute kidney damage in people who have either acute or chronic liver disease. Terlipressin infusion segment is expected to hold the dominant position in the market share due to the increasing demand because of its efficiency and applications against the condition.

Terlipressin injections are used to enhance kidney function in people with hepatorenal syndrome. Terlipressin injection causes splanchnic vasoconstriction, which shunts blood to the systemic circulation, reduces sympathetic nervous system and renin-angiotensin-aldosterone system activation, and blunts arginine vasopressin release, resulting in improved renal perfusion. Thus, the above factors are expected to hold the segment in the dominant market share.

Geographical Analysis

North America is expected to hold a significant position in the global hepatorenal syndrome market share

North America is expected to hold a dominant position in the market share owing to the increase in the number of drug approvals, increasing clinical trials and increasing pharmaceutical production in the region is expected to drive the market growth of the region.

For instance, On September 14, 2022, the FDA granted approval to terlipressin (Terlivaz) for the treatment of adults hospitalized with hepatorenal syndrome with rapid reduction in kidney function (HRS-1).

Additionally, the increasing disease prevalence in the region such as liver cirrhosis is also expected to drive the market growth in the region. As cirrhosis worsens, the risk of hepatorenal syndrome rises significantly. The serious complication of cirrhosis arises when the damaged liver disrupts blood flow to the kidneys which impacts the kidneys to filter waste and toxins from the blood. Thus, the above factors hold the region in the dominant position.

COVID-19 Impact Analysis

COVID-19 has impacted the market growth moderately. The increase in the research and development of COVID-19 medications has reduced the development of drugs for curing hepatorenal syndrome. The disruptions in the supply chain of the products across various regions and countries have also impacted the market growth.

Market Segmentation

By Type
• Type I
• Type II

By Treatment
• Liver Transplantation
• Terlipressin Infusion
• Albumin Infusion
• Hemodialysis
• Vasoconstrictors
• Antibiotic Therapy
Cefotaxime
Terlipressin
Norepinephrine and Midodrine
Octreotide

By End-User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The leading companies with a significant market share include Mallinckrodt plc, LEXICARE PHARMA PVT. LTD., Wellona Pharma, Taj Pharmaceuticals Limited, SiNi Pharma Pvt Ltd, MANUS AKTTEVA BIOPHARMA LLP, New Medicon Pharma Lab, B JOSHI AGROCHEM PHARMA, Cygnus Healthcare Specialities Pvt. Ltd. among others.

Why Purchase the Report?
• To visualize the global hepatorenal syndrome market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hepatorenal syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hepatorenal syndrome market report would provide approximately 58 tables, 60 figures, and 180 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies